Iktos

Iktos is a technology company specializing in artificial intelligence for new drug design. The company's mission is to leverage deep learning and artificial intelligence to change the way new therapeutic molecules are designed, significantly accelerating the drug discovery process. Iktos offers a range of innovative solutions tailored to different stages of drug discovery. Their flagship product, Makya, is a generative AI SaaS platform for de novo drug design, enabling medicinal and computational chemists to generate novel molecular structures with optimized properties. Spaya, another key offering, is an AI-based retrosynthesis planning software that helps chemists find the best synthetic routes for target molecules. The company has also ventured into robotics with Iktos Robotics, an automated synthesis platform that integrates AI for molecular design with robotic experimentation. Iktos' technology has been validated through multiple collaborations with pharmaceutical and biotech companies, demonstrating its ability to identify promising drug candidates more quickly and efficiently than traditional methods. By combining AI algorithms, big data, and expert knowledge in chemistry and drug design, Iktos aims to transform the drug discovery landscape, potentially reducing the time and cost associated with bringing new therapeutics to market.